Contribution of higher risk genes and European admixture to Crohn's disease in African Americans

Ming-Hsi Wang, Johns Hopkins University
Toshihiko Okazaki, Johns Hopkins University
Subra Kugathasan, Emory University
Judy H. Cho, Yale University
Kim L. Isaacs, University of North Carolina
James D. Lewis, University of Pennsylvania
Duane T. Smoot, Howard University
John F. Valentine, University of Florida
Howard A. Kader Kader, University of Maryland
Jean G. Ford, Johns Hopkins University

Only first 10 authors above; see publication for full author list.

Journal Title: Inflammatory Bowel Diseases
Volume: Volume 18, Number 12
Publisher: Oxford University Press (OUP): Policy B - Oxford Open Option B - CC-BY | 2012-12-01, Pages 2277-2287
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1002/ibd.22931
Permanent URL: https://pid.emory.edu/ark:/25593/sq6zq

Final published version: http://dx.doi.org/10.1002/ibd.22931

Copyright information:
© 2012 Crohn's & Colitis Foundation of America, Inc.

Accessed October 24, 2019 8:33 PM EDT
Contribution of higher risk genes and European admixture to Crohn's disease in African Americans

Ming-Hsi Wang, MD, PhD1,2, Toshihiko Okazaki, MD, PhD1, Subra Kugathasan, MD3, Judy H. Cho, MD4, Kim L. Isaacs, MD5, James D. Lewis, MD, MSCE6, Duane T. Smoot, MD7, John F. Valentine, MD8, Howard A. Kader, MD9, Jean G. Ford, MD10, Mary L. Harris, MD1,11, Maria Oliva-Hemker, MD12, Carmen Cuffari, MD12, Michael S. Torbenson, MD13, Richard H. Duerr, MD14, Mark S. Silverberg, MD, PhD15, John D. Rioux, PhD16, Kent D. Taylor, PhD17, Geoffrey C. Nguyen, MD, PhD1,15, Yuqiong Wu, MD1, Lisa W. Datta, MSc1, Stanley Hooker, BS18, Themistocles Dassopoulos, MD1,19, Rick A. Kittles, PhD18,20, Linda W.H. Kao, PhD10, and Steven R. Brant, MD1,10

1Lyn P. and Harvey M. Meyerhoff Inflammatory Bowel Disease Center, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 2Department of Medicine, St Agnes Hospital Center, Baltimore, MD 3Department of Pediatrics, Emory University, Emory, GA 4Department of Medicine and Genetics, Yale University, New Haven, CT 5Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC 6Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA 7Department of Medicine, Howard University College of Medicine, Washington, DC 8Division of Gastroenterology, Hepatology & Nutrition, University of Florida, Gainesville, FL 9Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD 10Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 11The Institute for Digestive Health & Liver Disease at Mercy Hospital, Baltimore, Maryland 12Division of Pediatric Gastroenterology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, MD 13Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 14Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh School of Medicine, and Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15Departments of Medicine, Surgery, Public Health Sciences, Immunology, and Molecular and Medical Genetics, University of Toronto, Samuel Lunenfeld Research Institute and Mount Sinai Hospital, Toronto, Canada; The Toronto General Hospital Research Institute, Toronto, Ontario, Canada 16Université de Montréal and the Montreal Heart Institute, Research Center, 5000 rue Belanger, Montreal, Quebec H1T 1C8, Canada.; The Broad Institute of MIT and Harvard, Cambridge, MA 17Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA 18Section of Genetic Medicine, Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, IL 19Gastroenterology Division, Washington University School of Medicine, St. Louis, MO 20Department of Medicine and Division of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, Illinois

Abstract

Background & Aims—African Americans (AA) are an admixed population of West African (WA) and European ancestry (EA). Crohn's disease (CD) susceptibility genes have not been
established. We therefore evaluated the contribution of European admixture and major established risk genes to AA CD.

Methods—Ninety-seven admixture informative markers were genotyped for ancestry estimates using STRUCTURE. 354 AA CD cases and 354 ethnicity-matched controls were genotyped for total 21 SNPs in ATG16L1, NOD2, IBD5, IL23R and IRGM by TaqMan or direct sequencing. Association was evaluated by logistic regression, adjusted for ancestry.

Results—Mean EA was similar among the CD cases and controls (20.9% and 20.4, respectively, p=0.58). No significant admixture differences were observed among cases (211 to 227) stratified by phenotypic sub-classifications including onset, surgery, site, and behavior. CD was associated with NOD2 carrier (6.93% CD, 2.15% Controls, p = 0.007), ATG16L1 Thr300Ala (36.1% CD, 29.3% Controls, p=0.003), SLC22A4 and SLC22A5 (IBD5 locus) functional SNPs (L503F [10.6% CD, 7.6% Controls, p=0.05] and g-207c [41.3% CD, 35.7% Controls, p=0.03], respectively) and IL23R rs2201841 (18.2% CD, 13.8% Controls, p=0.03), but not IRGM variants nor three African ancestral NOD2 nonsynonymous variants. IBD5 risk was recessive. An all-minor allele IBD5 haplotype from EA was associated (p=0.05), whereas a more common haplotype isolating g-207c was not.

Conclusions—Specific functional gene variations significantly contribute to AA CD risk. Established NOD2, SLC22A4-A5, and ATG16L1 variants show increased CD risk, with IBD5 in recessive. Although CD is more common in whites, European admixture is similar among AA cases and controls.

Keywords
genetics; epidemiology; Crohn's disease

Introduction

Historically, Crohn's disease (CD) incidence has been substantially lower in African Americans (AA) than white American populations. Some recent studies still show this, whereas two studies found hospitalization rates greatest among AA females.1, 2 AA CD prevalence in the population-based Kaiser Health Maintenance Organization study was two-thirds that of whites.2 Compared to most white populations, where ulcerative colitis (UC) occurs slightly more frequently than CD, in AA's CD incidence in children was observed 1.6-fold greater than UC suggesting potential etiological differences.3 CD phenotype features may also be different among races: we found AA's had significantly greater odds of colon-only and perianal disease, had lower odds of penetrating disease, and (for both CD and UC) greater odds of uveitis and sacroiliitis (2.1, 1.6, 0.52, 3.7 and 5.8-fold respectively).4 CD risk to AA siblings was much greater than population prevalence (2.5% vs. 45/100,000), suggesting that like white CD, AA CD likely has important genetic influences.4

The AA genome is an admixture of West African and European ancestry. When a phenotype is more common in one ancestral population compared to another, in an admixed population, the degree of genetic admixture in individuals with the phenotype often corresponds. For example, average BMI is greater in AA's than white Americans; correspondingly, BMI is inversely associated with degree of European ancestry in AA's.5 With CD more prevalent in whites than AA's, it is important to determine if overall CD risk arises from a relative increase in European admixture. It is also of interest to investigate whether phenotypic features more or less common in whites will correlate with the degree of European admixture.
Few studies have evaluated the influence of established CD molecular genetic risk factors in AA's. Nucleotide-binding oligomerization domain containing-2 (NOD2) mutations Arg702Trp, Gly908Arg and Leu1007fsinsC, the strongest, common CD risk factor in whites, was first evaluated in 58 AA children with CD and 124 healthy controls (HC's) from Wisconsin, but showed no association (carriers 3.8% CD vs. 4.3% HC's). We evaluated NOD2 in our initially recruited Mid-Atlantic (now Multicenter) African American IBD study (MAAIS – a sub-study of the NIDDK IBD Genetics Consortium [IBDGC]) of 183 CD and 143 HC's and found increased risk (8.2% vs. 2.1%, respectively, P=0.03). Given these discrepant findings, it is important that NOD2 AA risk be more substantiated. The IBD5 locus genes solute carrier family 22, member 4 and member 5 (SLC22A4 and SLC22A5) were the second genes having functional variations (Leu503Phe and g-207c, respectively) established as CD genetic risk factors. Whether both genes are required for CD risk and whether risk lies within variations that influence other proximal genes has not been discerned, primarily because of strong linkage disequilibrium (LD) within a single, common, minor allele haplotype found across a 600 kb region in whites. The first genome wide association study (GWAS) in whites established association for the interleukin (IL) 23 receptor gene, IL23R, the receptor product a key regulator of chronic inflammation in CD. Multiple IL23R single nucleotide polymorphisms (SNPs) have shown independent CD association with a poorly conserved albeit uncommon protective variant, Arg381Gln showing a greater than 3-fold protective effect. Autophagy 16 like-1 (ATG16L1) was the next CD gene established by GWAS; a Thr300Ala resulted in 1.5-fold risk. Of the established CD loci, NOD2, ATG16L1, SLC22A4-A5, IL23R and IRGM are among the highest risk CD genes (risk ≥ 1.4-fold) where functional variations have been identified and studied.

Methods

Patient Populations (summarized in Supplementary Table 1)

Primary dataset—The study population included unrelated individuals, self-identified as non-Hispanic AA with a history of confirmed CD, recruited from 2003 to 2007 by the MAAIS. Similarly, unrelated, self-identified non-Hispanic AA's with no personal or family history of inflammatory bowel disease (IBD) and no history of chronic diarrhea, unexplained abdominal pain, rectal bleeding or irritable bowel syndrome were recruited as non-IBD, ethnically matched HC's. MAAIS recruitment was coordinated at the Johns Hopkins Genetics Research Center (GRC) of the IBDGC with satellite recruitment at Howard University, University of Florida, University of North Carolina, University of Pennsylvania, and the Washington Hospital Center. Twenty-six AA cases, all patients at Johns Hopkins Hospital, and 13 AA healthy spouse controls were also included.
IBD family history was defined as IBD in first- or second-degree relatives. Smoking was an average of at least 1 cigarette daily for at least 3 months prior to diagnosis. CD diagnosis was confirmed by medical records review per the IBDGC standards in an operations manual.19

**Secondary dataset**—This dataset was derived primarily from DNA samples of 66 adults recruited at the University of Chicago and 59 children recruited at the Medical College of Wisconsin with confirmed CD.6, 20 DNAs from 12 AA children with confirmed CD were also received from a Duke University IBD study.21 Lastly, 43 samples were obtained from non-Hispanic, AA (or African-Canadian) individuals recruited by IBDGC GRC’s at University of Montreal, University of Pittsburgh, University of Toronto and Yale University. These DNA’s were purified from individuals with confirmed diagnoses of CD (n=14), UC (n=19), indeterminate colitis (n=3) and from 7 controls.4 Additional HC’s were from 152 AA’s, without known asthma, common rheumatologic diseases or UC, recruited by the Baltimore Asthma Severity Study. 22

**Phenotyping**

Phenotype features for the primary dataset was determined using a previously validated protocol, largely in accordance with the Montreal classification.19, 23 Age at diagnosis was by chart review or if necessary, patient questionnaire. Disease location (maximal extent) was classified as L1 (ileum involvement only), L2 (colonic involvement only), or L3 (ileocolonic). L4 (esophageal, gastric, duodenal or jejunal) involvement was determined independently of L1-L3. Disease behavior (B1-B3) was per the Montreal classification.24 History of surgery was confirmed bowel resection or diversion for treatment of CD or complications. Extra-intestinal disease was determined as previously reported.4

**Genotyping**

**Ancestry Estimation**—Ninety-six well DNA plates containing case and control samples on each plate, unique positioned water controls, 13 blinded duplicates and 5 blinded white controls were genotyped using 97 ancestry informative markers (AIM’s) by the Kittles laboratory as described.25, 26

**Candidate SNPs**—Samples from cases and HC’s were plated together, and laboratory personnel were blinded to disease status. Seventeen SNPs were genotyped using Applied Biosystem’s Taqman 5’-exonuclease assays, with alleles determined on an Applied Biosystems 7900HT Fast Real-Time PCR System analyzer. Three NOD2 SNPs (R702W, R708H, R790Q) were determined by direct sequencing of PCR products, and P268S was genotyped by PCR-RFLP.

**Statistical analysis**

**Admixture determination**—AIM genotypes from cases, HC’s, duplicates and unknown samples were compared with the same AIM genotypes from DNA samples of WA’s and Europeans. The data was used to determine fraction of European vs. WA ancestry using the program STRUCTURE 2.3 as described.26, 27 Each individual’s estimated percentage of WA and European ancestry was coded as a continuous variable. Individuals with more than 85% European ancestry were excluded from analyses.5 Power to observe a significant difference of European ancestry between AA cases and matched controls was calculated by assuming European ancestry differences from 1% to 5%, and alpha level 0.05, using SAS 9.1 package program (SAS Institute, Cary, NC).
Phenotype and demographic comparisons with admixture—Within cases, associations between WA ancestry and CD disease behaviors, sites of involvement, extra-intestinal disease, IBD family history and age at diagnosis were assessed by T-test, ANOVA, and logistic regression.

Genotype association analyses—Analyses were performed by SAS 9.1/Genetics package program (SAS Institute, Cary, NC). Two sample t-tests were used for continuous variables. Nominal data were analyzed using the χ² test. A two-tailed P < 0.05 was considered significant. Logistic regression model was used to calculate genetic association after adjusting calculated WA ancestry. Population attributable risk (PAR) was calculated as reported previously.28 For haplotype analysis, pairwise LD was calculated by PROC ALLELE using SAS 9.1. Association between each haplotype and risk of CD was estimated by regression substitution, a function implemented in the R program HaploStat.29 We applied Benjamini and Hochberg false discovery rate (FDR) to correct for multiple testing.30

Results

West African/European admixture analysis among MAAIS participants

We genotyped 227 confirmed CD cases and 201 HC’s from the primary dataset. Two AIMs were dropped because genotyping rates less than 20%. For the remaining 95 AIM’s, genotyping call rate was between 96.3% and 100%. Among the 13 blinded duplicate control paired samples, one DNA failed to genotype completely. For the remaining 12 pairs of 24 samples, genotyping call rate was 97%, and 99.6% of those genotypes called in both pairs were identical. For the five blinded white control subjects WA ancestry ranged from 2.1% to 5.0%. Among all MAAIS study subjects, calculated WA ancestry ranged from 28.6% to 97.5%, excluding one self-identified AA HC with 2.2% WA ancestry (i.e. 97.8% European ancestry). We had 29%, 56%, and 80% power to identify a significant difference in admixture of 2%, 3% and 4% based on a sample of 200 pairs of case and control.

Characteristics of the 227 MAAIS CD and 200 matched control patients with satisfactory AIM’s genotyping and WA ancestry greater than 15% are presented in Table 1. CD Study subjects showed a non-significant trend for younger age at study entry and female gender. There was no significant difference in tobacco use. Mean age at CD diagnosis was 26.8 (Standard Deviation [SD] 12.9) years and IBD family history 15.9%. Similar to our initial report, colon-only disease was relatively frequent (30.8%).4 Disease behavior was inflammatory (B1) in 40.5%, stricturing (B2) in 29.5%, and penetrating (B3) in 22.9%, with average length of observation between diagnosis and phenotype evaluation 10.8 years (SD 8.6 years).

Admixture and CD disease and phenotypes

There were no differences in overall mean estimated WA ancestry: 79.6% (SD 11.6%) in cases and 79.8% (SD11.9%) in HC’s (p=0.86). WA ancestry was not different by disease site: L1 80% (SD 12.4%), L2 80% (SD 10.1%), and L3 79% (SD 12.4%), p=0.13, and there was no difference in WA ancestry in ileal involvement (L1 and L3) vs. colon-only disease (L2) (p=0.55). WA ancestry did not differ by disease behavior: B1 81.2% (SD11.1%), B2 77.7% (SD12.6%) and B3 78.8% (SD 11.8%), p=0.17. There was a trend towards greater WA ancestry among persons with inflammatory disease (B1) relative to complicated disease (B2 or B3), WA ancestry 78.1% (SD 12.2) p=0.07. However, after excluding B1 with short length of disease (< 6 years), association evidence weakened, but most directly because of smaller sample size as WA ancestry percentage remained the same: WA ancestry B1 ≥6 years of disease 81.1% (SD 11.4) vs. B2 or B3 78.1% (SD 12.2), p=0.11. Mean WA ancestry did not differ by perianal disease (present 79.9%, absent 79.7%, p=0.7), by extra-
intestinal disease (present 80.8%, absent 79%; p=0.3), history of CD intestinal surgery (80% surgery, 79.3% no surgery; p=0.7), IBD family history (present 79%; absent 79.4%; p=0.9), or younger age at diagnosis (< age 40 at diagnosis 79.4%, ≥ age 40 at diagnosis 80.9%; p=0.5). Plots of cumulative proportion of WA ancestry for CD vs. HC’s, B1 vs. B2 or B3 behaviors, and L1 or L3 vs. L2 sites are shown in Figure 1.

West African/European ancestry among non-MAAIS study subjects (secondary dataset)

Mean WA ancestry was 78 to 80% for each subset of study subjects with the exception of the 27 IBD (10 CD) African Canadian cases and controls (n=4) from the Toronto and Montreal GRCs (mean WA ancestry 90%, consistent with the major origin of African Canadians from the Caribbean), and therefore these subjects were excluded for further genotyping. One study subject from University of Chicago, Medical College of Wisconsin and BASS recruitments each had more than 85% European ancestry and thus excluded from further analysis. Of the remaining study subjects, mean WA ancestry was 77.9% for the cases and 79.2% for controls (p=0.41). SNP genotyping quality using DNA's from ten cases was poor and were excluded from further analysis. This left a total of 127 CD cases and 154 HC’s in the secondary cohort for further analysis (Supplementary Table 1). For the combined primary and secondary datasets of 354 AA CD cases and 354 controls, mean EA remained highly similar (20.9% and 20.4%, p=0.58 respectively). We had 47%, 80% and 96% power to identify a significant difference in admixture of 2%, 3% and 4%, respectively, for this sample size.

Genotypic association studies

Genotype call rates were 97% or greater in both datasets, with the exception of the NOD2 SNPs genotyped by direct sequencing (95% call rate). Among HC’s, Hardy-Weinberg Equilibrium (HWE) was ≥ 0.07 for all SNPs except NOD2 R790Q (HWE 0.04) (Supplementary Table 2). Since there was no significant heterogeneity for any genotyped SNPs between primary and secondary datasets (Supplementary Table 3), to maximize power we analyzed genetic association for both datasets combined. (However, because we recruited cases and controls uniformly in the primary data set, we made their genotyping results available [Supplementary Table 4]).

NOD2

In the combined dataset (Table 2), presence of any NOD2 mutation (all simple heterozygotes) was significantly associated with CD (p = 0.007; FDR adjusted p= 0.02). NOD2 carriage rate was 7.1% CD, 2.2% HC’s with OR 3.28 (95%CI: 1.39 – 7.74). For the individual NOD2 risk mutations, only Leu1007fsinsC was significantly associated with CD (OR 8.08, 95%CI: 1.01-64.8, p=0.02; adjusted p = 0.04). Pro268Ser (“SNP5”), a common variant from European admixture, was significantly more frequent among cases (7.4% CD, 4.4% HCs, p=0.02). Using this marker to adjust for local (NOD2 region) admixture in AA’s, we still observed significant risk for the three NOD2 mutations (NOD2 carrier OR after adjusting SNP5 3.15, 95%CI: 1.16 – 8.56, p=0.01). We also observed that the three NOD2 mutations were more common among individuals with overall lower WA ancestry (76% WA in NOD2 carriers vs. 79.9% WA in NOD2 non-carriers, p=0.07), although not meeting criteria of statistical significance.

We sequenced the entire NOD2 coding exons and intron-exon boundaries in 31 AA CD cases and observed only three additional non-synonymous SNPs (in exon 4) that are uncommon or non-existent in Europeans (Supplementary Table 2): Arg708His, Ala725Gly and Arg790Gln. Since these 3 SNPs were proximal to Arg702Trp, and Arg702Trp genotyped poorly by TaqMan, we genotyped exon 4 SNPs by direct sequencing. However,
we did not find association evidence for any of these three apparently African ancestral SNPs (Table 2).

**ATG16L1**

In AA's, unlike Europeans, the variant G allele that encodes the300Ala CD risk residue, is the less common allele. Its frequency was 36.1% in CD compared with 29.3% in controls (p=0.003, adjusted p= 0.02). Analysis of genotypic relative risks showed that CD risk was significantly increased in both Thr/Ala heterozygotes (OR 1.49, 95%CI: 1.09-2.04, p=0.01) as well as Ala/Ala homozygotes (OR 1.86, 95%CI: 1.11-3.11, p=0.02) (Table 2).

**IBD5**

We genotyped five SNPs, which included functional variants Leu503Phe in *SLC22A4* and g-207c promoter variant in *SLC22A5*, and three marker SNPs more centromeric on the *IBD5* risk haplotype. Allelic association was found for Leu503Phe 10.5% CD, 7.6% HC, p=0.05 and g-207c 41.3% CD, 35.7% HC, p=0.03, with only g-207c marginally significant after correction for multiple testing (adjusted p=0.06; Table 2). Interestingly, genotypic analysis showed significant CD risk for all *IBD5* SNPs tested for homozygote but not heterozygote genotypes (Table 2). All five IBD5 SNPs remained significantly associated with CD for recessive mode of inheritance after FDR correction for multiple testing: *SLC22A4* L503F (adjusted p=0.05), *SLC22A5* g-207c (adjusted p = 0.02), IGR2230 (adjusted p=0.03), IGR2198 (adjusted p=0.02), IGR2096 (adjusted p=0.02).

**IL23R**

Analysis of five genotyped SNPs in *IL23R* suggested association only for variant alleles in intron7 SNP rs2201841 OR 1.39 (95%CI: 1.04-1.95, p=0.03, adjusted p=0.06). (Table 2). Only 4.0% of cases and 5.1% of HC's carried the 381Gltn protective variant (p=0.61).

**IRGM**

Analysis of variant allele frequency and genotypic relative risks for three *IRGM* SNPs, that included rs13361189 (in tight LD with the 20kb CNV) and rs10065172 (miRNA binding variant), showed no associations with CD (Table 2).

**Haplotype and Diplotype Analysis**

Strong LD was observed between *IBD5* variants but less between *IL23R* variants (Pairwise D′ values >0.65, r² value > 0.1; D′ values > 0.02, r² value > 0.004, respectively). When the most common *IBD5* haplotype, consisting of the five major alleles CGGCG is considered as reference, no association was observed for the second most common haplotype, consisting of four major alleles and the *SLC22A5* – g207c minor allele (CGGCG; 20.6% CD, 19.2% HC, p=0.24, Table 3). Similar to that observed in whites, significant risk was observed for the all-minor-allele haplotype TCAGT relative to the reference haplotype (9.8% CD, 7.1% HC, p=0.05). Diplotype association analysis found the only significant association was for individuals carrying homozygote variants in all five SNPs (TCAGT/TCAGT, OR 8.14, P=0.03) relative to the wild type diplotype (CGGCG/CGGCG), further supporting the recessive risk of *IBD5* (Supplementary Table 5). For 5-marker haplotype of *IL23R*, compared to the most common association haplotype TCGAT, there were two haplotypes suggesting association with CD (CAGGT P = 0.05, CCGAG P = 0.06, Table 3).

**Discussion**

*NOD2, SLC22A4, SLC22A5, IL23R, ATG16L1 and IRGM* are among the most highly investigated CD risk genes in white populations. This study, the first to evaluate in AA's...
SLC22A4 and SLC22A5, IL23R, ATG16L1, and IRGM and, with more than double the study population and adjustment for ancestral admixture, to re-evaluate NOD2, found significant association evidence for established risk alleles for all loci but IRGM. All studies in white populations have found NOD2 mutations more frequent among CD cases than controls, with a meta-analysis of 29 studies finding overall NOD2 carrier risk of 3.2.32 However, NOD2 mutations are rare or absent among non-white populations, the three NOD2 mutations assumed to have arisen in European ancestral populations or by admixture.33, 34 Our expanded study showed robust association evidence for carriage of any NOD2 mutation (OR 3.28, p=0.007; FDR adjusted p=0.02), with risk similar to whites,32 and significant association remained even after adjustment for individual admixture. However, because of lower frequency of mutations in AA’s, the estimated AA PAR was only 4.6 % vs. 22 % in whites.32 We also screened for and genotyped non-synonymous SNPs common in AA’s, to determine if any African ancestral NOD2 mutations contribute to CD risk, but found no association. Our study showed that in the AA population as in whites, common NOD2 risk only arises from the 3 major European ancestral loss of function mutations and for disease prediction purposes only these need to be genotyped. In white populations, NOD2 mutation homozygotes result in approximately 20-fold CD risk and are especially predictive of ileal involvement and complicated disease course.35 Indeed, NOD2 is now widely commercially available for these uses. However, we did not observe any NOD2 homozygotes in our AA CD study population (as opposed to 12% in a study of white CD patients from Baltimore, Chicago and Pittsburgh IBD centers),35 and with only 0.01% of the AA population predicted to be NOD2 homozygotes (as opposed to 0.5% homozygote rate found among combined white controls),36 NOD2’s clinical utility in AA’s should be specifically assessed prior to its routine use in this population.

Prior to GWAS, the IBD5 risk haplotype was the only other established genetic risk factor, with functional variants in SLC22A4 and SLC22A5 as the leading candidate risk variants, with risk present for both heterozygote and homozygote carriers, although numerous studies (including a recent meta-analysis) observed a gene-dosage effect, as did the original IBD5 discovery.8, 37 We observed significant association only for homozygote carriers, maximal for Leu503Phe with point OR estimates of 8.4, far greater than meta-analysis point OR observed in whites. In contrast to studies in whites, frequency of heterozygotes among AA’s for four IBD5 SNPs were actually lower among cases relative to controls, and for Leu503Phe heterozygotes had only a slight and non-significant increased presence relative to wild types (p=0.39).

The SLC22A5 –g207c functional variant, is frequently found in AA’s on a haplotype isolated from the other IBD5 minor alleles variants including the SLC22A4 Leu507Phe functional variant, However, SLC22A5 showed no evidence that it alone could cause CD risk. Rather, CD risk was only present in haplotype and diplotype analyses when both SLC22A4 and SLC22A5 functional alleles were found together and with the other minor alleles in the extended, apparently European origin IBD5 haplotype compatible with the finding from Fisher SA et al.38 Similar to the three established NOD2 risk mutations, SLC22A4 Leu503Phe appears to originate completely from European admixture, not being found in the Yoruban genome. One unifying hypothesis to explain risk in AA’s restricted to homozygotes vs. risk in whites only modestly increased in homozygotes relative to heterozygotes, is that within persons of EA, there might exist multiple albeit less frequent, additional SNPs besides Leu503Phe that similarly influence SLC22A4 epithelial transport activity, and thus some Leu/Leu wild types may be heterozygotes for less common SLC22A4 risk alleles, and some Leu/Phe heterozygotes may actually be compound homozygotes. A recent evolutionary analysis is consistent with this hypothesis.39 Thus, the true nature of IBD5 risk may be recessive for both white and AA populations. Interestingly,
IBD5 risk for UC was found significant in meta-analysis only for recessive and not for dominant inheritance.\textsuperscript{37}

IL23R was the first gene identified by European GWAS and proven as a significant risk for CD. We observed significant association in AA's with CD for intron7 IL23R SNP (rs2201841) (p=0.03), but no significant association was observed for other SNPs including the highly protective Arg381Gln variant – although power was limited given the 2.6% 381Gln allele frequency. In whites, rs2201841 has been shown as a risk factor independent of Arg381, and thus association evidence for rs2201841 may be important.\textsuperscript{28} Our haplotype analysis supported a role for IL23R in AA's showing nominal evidence for association for 2 of the 5 variant haplotypes with HC frequencies greater than 1\% (Table 3). Given the number of SNPs and haplotypes evaluated, larger studies are required to substantiate IL23R as a risk for AA CD.

Although frequency of the ATG16L1 functional 300Ala variant is lower in AA's than observed in our population-based study in Canadian whites (29\% AA HC vs. 52\% white HC's), we observed similar and highly significant association (OR 1.41, p=0.003) with CD.\textsuperscript{28} Given that 300Ala is relatively frequent in Yorubans (27.5\%), unlike NOD2 and SLC22A4 – in AA's the origin of the ATG16L1 functional variant risk is likely contributed by both ancestral populations.

IRGM, which encodes a GTP-binding protein that induces autophagy and plays an important role against intracellular pathogens, was recognized as CD risk gene by the Wellcome Trust GWAS.\textsuperscript{16} A 20 kb promoter deletion in whites has been associated with reduced IRGM expression in several cell types.\textsuperscript{16} We genotyped this 20 kb CNV in 96 AA's and observed that similar to whites, the rs13361189 “c” allele was in perfect LD with the 20kb deletion (data not shown), these minor alleles are nearly 20-fold more frequent in AA's relative to whites. There is some controversy with regard to the influence of the 20 kb CNV: in a well-powered Japanese study the CNV deletion polymorphism, although as in AA's also found at relatively high frequency, also observed nearly identical presence among CD cases and controls (37\% and 38\%, respectively).\textsuperscript{17} Hence, the background ancestry appears to have a controlling influence on the 20kb CNV risk. However, our power to exclude risk was more limited (51\%-78\% [Supplementary Table 6] vs. 90\% in the Japanese study).\textsuperscript{17} Similarly, neither our study nor the Japanese study observed risk for rs10065172, reported to influence miRNA regulation of IRGM expression, and likewise found at high frequency in both Japanese and AA's. One possible explanation for this observed lack of IRGM association with CD in Japanese and AA is that, as proposed by Prescott et al., the true causal variant is neither the CNV nor rs10065172, but arose on a haplotype in Europeans after the split with African and Asian populations.\textsuperscript{17}

AAs are a recently admixed population with an average of $\sim$80\% of African ancestry but significant variation exists at individual level.\textsuperscript{40, 41} Studies of disease or phenotype patterns, including obesity, skin pigmentation, psychiatric disorders, and asthma in AAs have shown that African ancestry is different between cases and ethnicity matched controls from less than 1\% to 4\%.\textsuperscript{5, 42-44} This study is the first large population-based study to investigate the association between African ancestry and CD risk in AAs. Nonetheless, admixture was essentially identical. This was despite the fact that NOD2 and IBD5 loci – both with greater than 3-fold risks in our study - clearly arise only from European admixture. One explanation may be the relatively low protection from CD – perhaps counterbalancing the NOD2 and IBD5 risks – of IL23R 381Gln (present in only 5\% of healthy AA's vs. 14\% of healthy whites). Other considerations include the possibility that there may exist high risk, African ancestry variants yet to be discovered, and that our study had suboptimal power to identify modest admixture differences below 3\%. Admixture analysis did not identify any significant
associations within CD sub-phenotypes and demographic features. Power was even more limited for these analyses, however, and it will be of great interest to evaluate potential admixture-phenotype expression features in a larger study population, especially for features where a trend was observed, notably inflammatory vs. complicated disease behavior.

We previously provided the first evidence that family history of CD in AA's was significant, suggesting that as in whites, AA CD would likely have genetic origins. In the present study, we have provided strong evidence to support our previous modest evidence that established NOD2 mutations contribute to CD risk in AA's, and provide evidence that established functional polymorphisms in SLC22A4 and ATG16L1, and possibly an intronic polymorphism in IL23R also contribute to AA CD risk. Unexpected findings of our study include the nature of IBD5 risk as most likely recessive, the ability to isolate – likely from the greater diversity of the African genome – the −g207c SLC22A5 risk allele and by haplotype analysis provide evidence against it as a CD risk factor alone, and that the degree of European admixture in CD and HC's would be so similar. This study represents an initial characterization of CD genetic risk in AA's. This study shows that the established CD risk genes in whites, NOD2, IBD5, and ATG16L1, also contribute to the risk of CD in AAs without influence by their African ancestry. This finding could become increasingly more critical with commercial laboratories now incorporating CD gene testing to predict disease risk. Future studies evaluating additional established CD genes, with larger study populations and more dense genotyping, as well as AA GWAS's to identify unique African ancestral risk as well as protective variants are greatly anticipated to further elucidate the nature of CD genetics in this under-investigated population.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Grant Support: This study is supported primarily by NIH grant DK062431 (SRB) with a supplement to assist with patient recruitment from the NCMHD. Additional funding was from the Harvey M. and Lynn P. Meyerhoff Inflammatory Bowel Disease Center, the Morton Hyatt Family, the Atran Foundation, and the Buford and Linda Lewis family. MHW also received support from St Agnes Hospital and Geoffrey Nguyen was supported by an AGA Research Scholar Award. Additional IBDGC support was from DK062429 and DK062422 (JHC), DK062420 (RHD), DK062432 (JDR), DK062423 (MSS), and DK062413 (KT).

We thank the patients and the controls for participating in this study. We thank Patricia Ushry and Vivian Abadom, Johns Hopkins University; Dolly Walkup, RN and Mikki Sandridge, University of North Carolina; Susan Parrott, RN, University of Pennsylvania; Dr. Michelle Mendoza, Washington Hospital Center; Amy Gunnett, RN and Gretchen Simpkins, RN, University of Florida; and Melvin Hall, Howard University Hospital for coordinating recruitment at each site. We thank Dr. Michael S. Gold and Dr. Averell Sherker (now at NIDDK) for organizing recruitment at Washington Hospital Center, Washington, DC. We thank Theodore M. Bayless, MD, John Kwon, MD, Sharon Dudley-Brown, PhD, LNP, Mark Lazarev, MD, Florin Selaru, MD, and Tina Ha, MD from the Meyerhoff IBD Center for their patient referrals. We thank Dr. Gerald Canakis, Atlantic General Hospital, Berlin, MD; Dr. Ray Cross, University of Maryland, Baltimore, MD; and Dr. Carlton Greene and Dr. Edward Wolf, Baltimore, MD for patient referrals. We thank the Maryland, D.C. and Northern Virginia Chapter of the Crohn's Colitis Foundation of America for advertisement of our study. The database was developed with assistance by Phil Schumm (University of Chicago).

References


**Abbreviations used in this paper**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>African American</td>
</tr>
<tr>
<td>WA</td>
<td>West African</td>
</tr>
<tr>
<td>EA</td>
<td>European ancestry</td>
</tr>
<tr>
<td>CD</td>
<td>Crohn's disease</td>
</tr>
<tr>
<td>UC</td>
<td>ulcerative colitis</td>
</tr>
<tr>
<td>HC</td>
<td>healthy controls</td>
</tr>
<tr>
<td>MAAIS</td>
<td>Multicenter African American IBD Study</td>
</tr>
<tr>
<td>IBDGC</td>
<td>IBD Genetics Consortium</td>
</tr>
<tr>
<td>LD</td>
<td>linkage disequilibrium</td>
</tr>
<tr>
<td>NOD2</td>
<td>Nucleotide-binding oligomerization domain containing-2</td>
</tr>
<tr>
<td>SLC22A4</td>
<td>Solute carrier family 22, member 4</td>
</tr>
<tr>
<td>SLC22A5</td>
<td>Solute carrier family 22, member 5</td>
</tr>
<tr>
<td>GWAS</td>
<td>genome wide association study</td>
</tr>
<tr>
<td>IL23R</td>
<td>interleukin (IL) 23 receptor</td>
</tr>
<tr>
<td>SNP</td>
<td>single nucleotide polymorphism</td>
</tr>
<tr>
<td>ATG16L1</td>
<td>autophagy 16 like-1</td>
</tr>
<tr>
<td>IRGM</td>
<td>immunity-related GTPase family, M</td>
</tr>
<tr>
<td>CNV</td>
<td>copy number variation</td>
</tr>
<tr>
<td>IBD</td>
<td>inflammatory bowel disease</td>
</tr>
<tr>
<td>GRC</td>
<td>Genetics Research Center</td>
</tr>
<tr>
<td>AIM</td>
<td>admixture informative marker</td>
</tr>
<tr>
<td>PAR</td>
<td>population attributable risk</td>
</tr>
<tr>
<td>HWE</td>
<td>Hardy-Weinberg Equilibrium</td>
</tr>
</tbody>
</table>
Cumulative proportion of persons with increment of West African ancestry for (a) CD (solid) vs. controls (dashed); (b) complicated (B2 or B3) (solid) vs. inflammatory behavior (dashed); and (c) ileal (L1 or L3) (solid) vs. colon-only (L2) disease (dashed) sites. Linear regression analyses treating WA as a continuous trait observed a borderline difference in complicated vs. inflammatory behavior (p=0.07), and no differences in CD vs. controls (p=0.57) or ileal vs. colon-only sites (p=0.55).
**Table 1**
Baseline and clinical characteristics of cases (Crohn's disease) and controls (HC) in primary dataset (MAAIS)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>CD (n=227)</th>
<th>HC (n=200)</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at enrollment (years)</td>
<td>37.4 ± 14.3</td>
<td>39.8 ± 12.7</td>
<td>0.07</td>
</tr>
<tr>
<td>Age at diagnosis</td>
<td>26.7 ± 12.9</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Gender (Male %)</td>
<td>34.2%</td>
<td>42.6%</td>
<td>0.08</td>
</tr>
<tr>
<td>Family history of IBD (%)§</td>
<td>15.9%</td>
<td>0.0%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cigarette smoking status:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never (%)</td>
<td>136 (65%)</td>
<td>91 (51.7%)</td>
<td>0.05</td>
</tr>
<tr>
<td>Former (%)</td>
<td>15 (7.1%)</td>
<td>20 (11.3%)</td>
<td></td>
</tr>
<tr>
<td>Current (%)</td>
<td>58 (27.9%)</td>
<td>65 (37%)</td>
<td></td>
</tr>
<tr>
<td>CD disease behavior</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B1: Inflammatory</td>
<td>92 (40.5%)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>B2: Stricture</td>
<td>67 (29.5%)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>B3: Penetrating (fistulizing)</td>
<td>52 (22.9%)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Disease location</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L1: Ileal</td>
<td>49 (21.6%)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>L2: Colonic</td>
<td>70 (30.8%)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>L3: ileocolonic</td>
<td>103 (45.3%)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>L4: isolated upper disease</td>
<td>2 (0.9%)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Any Perianal Disease§</td>
<td>70 (30.7%)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Surgical Resection for CD§</td>
<td>104 (46.0%)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>West African ancestry estimates (%)</td>
<td>0.796 +/- 0.116</td>
<td>0.798 +/- 0.119</td>
<td>0.86</td>
</tr>
</tbody>
</table>

§Unknowns were 8 for family history, 13 for perianal, and 4 for surgery
### Table 2

Association of SNPs for established CD genes among 354 CD cases and 354 controls (combined cohort dataset)

<table>
<thead>
<tr>
<th>Candidate Gene</th>
<th>SNP no.</th>
<th>0 copy of variant allele</th>
<th>1 copy of variant allele</th>
<th>2 copies of variant allele</th>
<th>Carrier</th>
<th>MAF case/control</th>
<th>OR (95%CI)</th>
<th>P value</th>
<th>FDR adjusted p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOD2 C_insertion</td>
<td>rs2066847 (L1007fs-insC (SNP13))</td>
<td>343/350 (ref)</td>
<td>8/1</td>
<td>8.16 (1.02- 65.6) 0.05</td>
<td>0/0</td>
<td>--</td>
<td>8.16 (1.02 – 65.6) 0.05</td>
<td>1.14% / 0.14%</td>
<td>8.08 (1.01-64.8) 0.02</td>
</tr>
<tr>
<td>NOD2 (G-&gt;C, variant C)</td>
<td>rs2066845 (G908R (SNP12))</td>
<td>347/347 (ref)</td>
<td>4/2</td>
<td>2.00 (0.36-10.9) 0.42</td>
<td>0/0</td>
<td>--</td>
<td>2.00 (0.36-10.9) 0.42</td>
<td>0.57% / 0.29%</td>
<td>1.99 (0.36-10.9) 0.42</td>
</tr>
<tr>
<td>NOD2 (C-&gt;T, variant T)</td>
<td>rs2066844 (R702W (SNP8))</td>
<td>334/327 (ref)</td>
<td>11/4</td>
<td>2.69 (0.85-8.54) 0.09</td>
<td>0/0</td>
<td>--</td>
<td>2.69 (0.85-8.54) 0.09</td>
<td>1.59% / 0.60%</td>
<td>2.66 (0.84-8.41) 0.08</td>
</tr>
<tr>
<td>NOD2 carrier (any 1007fs, G908R, R702W)</td>
<td>rs2066842 (P268S (SNP5))</td>
<td>304/319 (ref)</td>
<td>40/31</td>
<td>1.35 (0.83-2.22) 0.22</td>
<td>6/0</td>
<td>8.53 (1.01-65.6) 0.03</td>
<td>1.35 (0.83-2.22) 0.22</td>
<td>7.43% / 4.43%</td>
<td>1.73 (1.10-2.74) 0.02</td>
</tr>
<tr>
<td>NOD2 (C-&gt;T, variant T)</td>
<td>rs2066844 (R708H (SNP8))</td>
<td>333/322 (ref)</td>
<td>12/9</td>
<td>1.29 (0.54-3.10) 0.57</td>
<td>0/0</td>
<td>1.29 (0.54-3.10) 0.57</td>
<td>1.29 (0.54-3.10) 0.57</td>
<td>7.43% / 4.43%</td>
<td>1.73 (1.10-2.74) 0.02</td>
</tr>
<tr>
<td>NOD2 (G-&gt;A, variant A)</td>
<td>rs5743279 (R790Q)</td>
<td>333/322 (ref)</td>
<td>26/23</td>
<td>1.09 (0.61-1.95) 0.78</td>
<td>1/2</td>
<td>0.48 (0.01-9.30) 0.97</td>
<td>1.09 (0.61-1.95) 0.78</td>
<td>7.43% / 4.43%</td>
<td>1.73 (1.10-2.74) 0.02</td>
</tr>
<tr>
<td>ATG16LI (A-&gt;G, variant G)</td>
<td>rs2241880 (Thr300Ala)</td>
<td>141/179 (ref)</td>
<td>44/33</td>
<td>1.86 (1.11-3.11) 0.02</td>
<td>1/2</td>
<td>1.55 (1.15-2.10) 0.004</td>
<td>1.86 (1.11-3.11) 0.02</td>
<td>36.1% / 20.3%</td>
<td>1.41 (1.12-1.76) 0.003</td>
</tr>
<tr>
<td>IBD5_OCTN1 SLC22A4 (C-&gt;T, variant T)</td>
<td>rs1050152 (Leu503Phe)</td>
<td>285/297 (ref)</td>
<td>58/51</td>
<td>1.19 (0.79-1.79) 0.42</td>
<td>8/1</td>
<td>8.34 (1.01-67.1) 0.04</td>
<td>1.19 (0.79-1.79) 0.42</td>
<td>10.9% / 7.59%</td>
<td>1.43 (1.00-2.07) 0.05</td>
</tr>
<tr>
<td>IBD5_OCTN2 SLC22A5 (G-&gt;C, variant C)</td>
<td>rs2631367 (G702W (SNP8))</td>
<td>263/261 (ref)</td>
<td>116/163</td>
<td>1.02 (0.74-1.41) 0.91</td>
<td>63/36</td>
<td>1.89 (1.17-3.15) 0.05</td>
<td>1.02 (0.74-1.41) 0.91</td>
<td>41.3% / 35.7%</td>
<td>1.26 (1.02-1.57) 0.03</td>
</tr>
<tr>
<td>IBD5_OCTN2 SLC22A4 (G-&gt;T, variant T)</td>
<td>rs1009152 (Leu603Phe)</td>
<td>124/134 (ref)</td>
<td>163/173</td>
<td>1.00 (0.71-1.39) 1.00</td>
<td>22/8</td>
<td>2.85 (1.19-7.56) 0.05</td>
<td>1.00 (0.71-1.39) 1.00</td>
<td>21.9% / 18.7%</td>
<td>1.22 (0.94-1.59) 0.13</td>
</tr>
<tr>
<td>IBD5_OCTN2 SLC22A5 (G-&gt;C, variant C)</td>
<td>rs1762220 (G908R (SNP12))</td>
<td>176/222 (ref)</td>
<td>108/113</td>
<td>1.00 (0.71-1.39) 1.00</td>
<td>22/8</td>
<td>2.85 (1.19-7.56) 0.05</td>
<td>1.00 (0.71-1.39) 1.00</td>
<td>21.9% / 18.7%</td>
<td>1.22 (0.94-1.59) 0.13</td>
</tr>
<tr>
<td>IBD5_OCTN2 SLC22A5 (G-&gt;C, variant C)</td>
<td>rs171919135</td>
<td>99/113</td>
<td>15/3</td>
<td>0.96 (0.65-1.42) 0.89</td>
<td>15/2</td>
<td>7.56 (1.73-68.8) 0.03</td>
<td>1.13 (0.78-1.63) 0.56</td>
<td>14.7% / 11.7%</td>
<td>1.27 (0.95-1.77) 0.10</td>
</tr>
<tr>
<td>IBD5_OCTN2 SLC22A4 (G-&gt;T, variant T)</td>
<td>rs1251868</td>
<td>260/263 (ref)</td>
<td>72/76</td>
<td>0.96 (0.65-1.40) 0.89</td>
<td>15/2</td>
<td>7.56 (1.73-68.8) 0.03</td>
<td>1.13 (0.78-1.63) 0.56</td>
<td>14.7% / 11.7%</td>
<td>1.27 (0.95-1.77) 0.10</td>
</tr>
<tr>
<td>IL23R (T-&gt;G, variant G)</td>
<td>rs2517847</td>
<td>227/212 (ref)</td>
<td>100/126</td>
<td>0.74 (0.54-1.02) 0.07</td>
<td>21/12</td>
<td>1.63 (0.79-3.40) 0.19</td>
<td>0.82 (0.60-1.11) 0.20</td>
<td>20.4% / 21.4%</td>
<td>0.94 (0.73-1.22) 0.64</td>
</tr>
<tr>
<td>Candidate Gene</td>
<td>SNP no.</td>
<td>0 copy of variant allele</td>
<td>1 copy of variant allele</td>
<td>2 copies of variant allele</td>
<td>Carrier</td>
<td>MAF case/control</td>
<td>Minor Allelic test</td>
<td>FDR adjusted p value</td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>---------</td>
<td>--------------------------</td>
<td>--------------------------</td>
<td>---------------------------</td>
<td>---------</td>
<td>-----------------</td>
<td>-------------------</td>
<td>---------------------</td>
<td></td>
</tr>
<tr>
<td>IL23R (A→G, variant G)</td>
<td>rs2201841</td>
<td>231/263 (ref)</td>
<td>101/81</td>
<td>1.42 (1.00-2.03)</td>
<td>0.05</td>
<td>12/8</td>
<td>1.71 (0.63-4.90)</td>
<td>0.35</td>
<td>1.45 (1.08-2.04)</td>
</tr>
<tr>
<td>IL23R (G→A, variant A)</td>
<td>rs11209026</td>
<td>333/333 (ref)</td>
<td>14/18</td>
<td>0.78 (0.35-1.69)</td>
<td>0.61</td>
<td>0/0</td>
<td>--</td>
<td>0.78 (0.35-1.69)</td>
<td>0.61</td>
</tr>
<tr>
<td>IL23R (T→C, variant C)</td>
<td>rs1495965</td>
<td>98/103 (ref)</td>
<td>17/83</td>
<td>1.01 (0.71-1.42)</td>
<td>0.98</td>
<td>72/65</td>
<td>1.16 (0.75-1.80)</td>
<td>0.40</td>
<td>1.05 (0.75-1.45)</td>
</tr>
<tr>
<td>IL23R (C→A, variant A)</td>
<td>rs10889677</td>
<td>234/254 (ref)</td>
<td>102/89</td>
<td>1.24 (0.88-1.77)</td>
<td>0.23</td>
<td>9/7</td>
<td>1.40 (0.45-4.48)</td>
<td>0.69</td>
<td>1.26 (0.98-1.67)</td>
</tr>
<tr>
<td>IRGM (G→A, variant A)</td>
<td>rs4958847</td>
<td>102/96 (ref)</td>
<td>163/97</td>
<td>0.92 (0.65-1.31)</td>
<td>0.64</td>
<td>83/87</td>
<td>0.90 (0.60-1.35)</td>
<td>0.61</td>
<td>0.91 (0.66-1.27)</td>
</tr>
<tr>
<td>IRGM (T→C, variant C)</td>
<td>rs13361189</td>
<td>112/130 (ref)</td>
<td>153/165</td>
<td>0.97 (0.69-1.38)</td>
<td>0.36</td>
<td>73/75</td>
<td>0.96 (0.63-1.45)</td>
<td>0.83</td>
<td>0.97 (0.70-1.33)</td>
</tr>
<tr>
<td>IRGM (C→T, variant T)</td>
<td>rs10065172</td>
<td>114/109 (ref)</td>
<td>164/166</td>
<td>0.95 (0.67-1.33)</td>
<td>0.74</td>
<td>71/75</td>
<td>0.91 (0.60-1.37)</td>
<td>0.64</td>
<td>0.93 (0.68-1.28)</td>
</tr>
</tbody>
</table>
### Table 3

**Haplotype analysis of IBD5 and IL23R**

<table>
<thead>
<tr>
<th>Candidate gene</th>
<th>Haplotype</th>
<th>Cases</th>
<th>Controls</th>
<th>OR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>IBD5</em> (rs1050152 C&gt;T, rs2631367 G&gt;C, rs1762208 G&gt;A, rs11739135 C&gt;G, rs12521868 G&gt;T)</td>
<td>CGGCG</td>
<td>55.9%</td>
<td>61.1%</td>
<td>ref</td>
<td>Global P=0.43</td>
</tr>
<tr>
<td></td>
<td>-C---</td>
<td>20.6%</td>
<td>19.2%</td>
<td>1.18 (0.89-1.57)</td>
<td>0.24</td>
</tr>
<tr>
<td></td>
<td>TCAGT</td>
<td>9.8%</td>
<td>7.1%</td>
<td>1.47 (0.99-2.18)</td>
<td>0.05</td>
</tr>
<tr>
<td></td>
<td>-CA--</td>
<td>8.0%</td>
<td>7.1%</td>
<td>1.26 (0.83-1.90)</td>
<td>0.28</td>
</tr>
<tr>
<td></td>
<td>--AGT</td>
<td>1.6%</td>
<td>2.4%</td>
<td>0.75 (0.33-1.71)</td>
<td>0.49</td>
</tr>
<tr>
<td></td>
<td>-CAGT</td>
<td>2.0%</td>
<td>1.9%</td>
<td>1.27 (0.53-3.04)</td>
<td>0.60</td>
</tr>
<tr>
<td></td>
<td>TCGAT</td>
<td>34.5%</td>
<td>35.2%</td>
<td>ref</td>
<td>Global P=0.03</td>
</tr>
<tr>
<td></td>
<td>C----</td>
<td>27.8%</td>
<td>31.3%</td>
<td>0.88 (0.66-1.16)</td>
<td>0.37</td>
</tr>
<tr>
<td></td>
<td>--G</td>
<td>13.9%</td>
<td>15.6%</td>
<td>0.85 (0.60-1.22)</td>
<td>0.39</td>
</tr>
<tr>
<td></td>
<td>CA-G</td>
<td>14.8%</td>
<td>9.8%</td>
<td>1.45 (1.00-2.09)</td>
<td>0.05</td>
</tr>
<tr>
<td></td>
<td>-A-GG</td>
<td>1.2%</td>
<td>2.1%</td>
<td>0.67 (0.25-1.82)</td>
<td>0.43</td>
</tr>
<tr>
<td></td>
<td>C--G</td>
<td>3.3%</td>
<td>1.6%</td>
<td>2.59 (0.96-6.98)</td>
<td>0.06</td>
</tr>
<tr>
<td></td>
<td>--A-G</td>
<td>1.3%</td>
<td>0.6%</td>
<td>1.87 (0.44-8.02)</td>
<td>0.40</td>
</tr>
</tbody>
</table>

*Inflamm Bowel Dis. Author manuscript, available in PMC 2013 December 01.*